Pesquisar
Relay Therapeutics Inc
RLAYAdicionar à lista de desejos
18.830USD
-0.620-3.19%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
4.06BValor de mercado
PerdaP/L TTM
Mais detalhes de Relay Therapeutics Inc Empresa
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Informações de Relay Therapeutics Inc
Código da empresaRLAY
Nome da EmpresaRelay Therapeutics Inc
Data de listagemJul 16, 2020
CEOPatel (Sanjiv K)
Número de funcionários261
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 16
Endereço60 Hampshire Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139
Telefone16173708837
Sitehttps://relaytx.com/
Código da empresaRLAY
Data de listagemJul 16, 2020
CEOPatel (Sanjiv K)
Executivos da empresa Relay Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
229.91K
+22.16%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
219.76K
-21.36%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexis A. Borisy
Mr. Alexis A. Borisy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
229.91K
+22.16%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
219.76K
-21.36%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Relay Therapeutics Inc?
Os cinco principais acionistas de Relay Therapeutics Inc são: Dr. Mark Murcko, Ph.D.
Quantas instituições possuem ações da Relay Therapeutics Inc (RLAY)?
Em 2026Q1, 474 instituições possuíam ações da Relay Therapeutics Inc, com valor de mercado aproximado de 194.30M, representando 101.48% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3648091.00.